X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors.
Lead Product(s): OKI-219,Fulvestrant
Therapeutic Area: Oncology Product Name: OKI-219
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Reneo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 13, 2024
Details:
The combined company will advance OnKure’s pipeline targeting oncogenic mutations in PI3K alpha, including its lead program OKI-219, which is in Phase 1 trial for the treatment of solid tumors.
Lead Product(s): OKI-219,Fulvestrant
Therapeutic Area: Oncology Product Name: OKI-219
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Reneo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 13, 2024
Details:
OKI-219 is a potential best-in-class, orally bioavailable, highly selective inhibitor of PI3Kα H1047R, which is being evaluated for the treatment of HER2+/ PI3Kα H1047R breast cancer.
Lead Product(s): OKI-219
Therapeutic Area: Oncology Product Name: OKI-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The proceeds will be used to support the continued development of OnKure’s differentiated pipeline of next generation precision medicines, including the advancement of its lead discovery program OKI-219, a selective PI3K alpha H1047R inhibitor, into the clinic.
Lead Product(s): OKI-219
Therapeutic Area: Oncology Product Name: OKI-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Surveyor Capital
Deal Size: $54.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 23, 2023
Details:
OKI-179 is a novel, oral Class I histone deacetylase (HDAC) inhibitor for the potential treatment of a wide range of solid and hematological malignancies.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
OKI-179 combined with binimetinib in NRAS-mutated melanoma or combined with binimetinib + encorafenib in BRAF-mutated colorectal xenografts showed significantly increased regressions compared to either single agent following two weeks of dosing.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
OKI-179, a novel oral Class I histone deacetylase inhibitor for treatment of wide range of solid and hematological malignancies, increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma.
Lead Product(s): OKI-179,Binimetinib
Therapeutic Area: Oncology Product Name: OKI-179
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Colorado
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
